TARS Earnings Tarsus Pharmaceuticals, Inc.
Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Updated
Annual results
EPS
Revenue
Net income
Quarterly results
EPS
Revenue
Net income
Reported EPS history
1–26 of 26
| Q2 2026 | 2026-06-30 | -0.59 | 2026-08-06 | 10-Q |
| Q1 2026 | 2026-03-31 | -0.16 | 2026-05-06 | 10-Q |
| FY 2025 | 2025-12-31 | -1.59 | 2026-02-23 | 10-K |
| Q3 2025 | 2025-09-30 | -1.40 | 2025-11-04 | 10-Q |
| Q2 2026 | 2025-06-30 | -1.11 | 2026-08-06 | 10-Q |
| Q1 2026 | 2025-03-31 | -0.64 | 2026-05-06 | 10-Q |
| FY 2025 | 2024-12-31 | -3.07 | 2026-02-23 | 10-K |
| Q3 2025 | 2024-09-30 | -2.48 | 2025-11-04 | 10-Q |
| Q2 2025 | 2024-06-30 | -1.89 | 2025-08-06 | 10-Q |
| Q1 2025 | 2024-03-31 | -1.01 | 2025-05-01 | 10-Q |
| FY 2025 | 2023-12-31 | -4.62 | 2026-02-23 | 10-K |
| Q3 2024 | 2023-09-30 | -3.35 | 2024-11-13 | 10-Q |
| Q2 2024 | 2023-06-30 | -2.05 | 2024-08-08 | 10-Q |
| Q1 2024 | 2023-03-31 | -0.88 | 2024-05-08 | 10-Q |
| FY 2024 | 2022-12-31 | -2.52 | 2025-02-25 | 10-K |
| Q3 2023 | 2022-09-30 | -2.03 | 2023-11-09 | 10-Q |
| Q2 2023 | 2022-06-30 | -1.15 | 2023-08-10 | 10-Q |
| Q1 2023 | 2022-03-31 | -0.98 | 2023-05-09 | 10-Q |
| FY 2022 | 2021-12-31 | -0.67 | 2023-03-17 | 10-K |
| Q3 2022 | 2021-09-30 | 0.05 | 2022-11-09 | 10-Q |
| Q2 2022 | 2021-06-30 | 0.76 | 2022-08-11 | 10-Q |
| Q1 2022 | 2021-03-31 | 0.47 | 2022-05-11 | 10-Q |
| FY 2021 | 2020-12-31 | -4.32 | 2022-03-14 | 10-K |
| Q3 2021 | 2020-09-30 | -5.73 | 2021-11-10 | 10-Q |
| Q2 2021 | 2020-06-30 | -1.96 | 2021-08-05 | 10-Q |
| Q1 2021 | 2020-03-31 | -0.74 | 2021-05-11 | 10-Q |
Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Informational only — not financial advice.